Considerable efforts have been made over the past several years to discover a broad-spectrum antipicornavirus agent. The X-ray crystal structure of several rhinovirus serotypes, as well as a coxsackievirus, has provided valuable information with respect to the virus structure as well as the location of the binding site of several capsid-binding compounds. This has aided in the design of broad-spectrum compounds. Several potential drug candidates have reached clinical status and some progress has been made in achieving efficacy. However, none of these compounds has as yet become a marketable drug. This review summarizes the current status of efforts in this area.
AbrahamG & ColonnoRT (1984) Many rhinovirus serotypes share the same cellular receptor. Journal of Virology51:340–345.
2.
Al-NakibWHigginsRBarrowITyrellDAJLenox-SmithI & IshitsukaH (1987a) Intranasal chalcone Ro 0410, as prophylaxis against rhinovirus infections in human volunteers. Journal of Antimicrobial Chemotherapy20:887–892.
3.
Al-NakibWHigginsPGBarrowIBalstoneG & TyrellDA (1987b) Prophylaxis and treatment of rhinovirus colds with zinc gluconate. Antimicrobial Agents and Chemotherapy20:893–901.
4.
Al-NakibWHigginsPGBarrowGITyrellDAJAndriesKVanden BusscheGTaylorN & JanssenP (1989) Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug. Antimicrobial Agents and Chemotherapy33:522–525.
5.
AndriesKDewindtBSnoeksJWillebrordsKVan EemerenK & StokbroekxK (1991) Antirhinovirus spectrum and mechanism of action of R77975. Antiviral Research15 (Supplement 1): Abstract 101.
6.
AndriesKStokbroekxRDewindtB & SnoeksJ (1992) In vitro activity of pirodavir (R77975), a substituted phenoxy-pyridazinamine with broad spectrum antipicornaviral activity. Antimicrobial Agents and Chemotherapy36:100–107.
7.
ArrudaECrumpCEMartinSDMerluzziVJ & HaydenFG (1992) In vitro studies of the antirhinovirus activity of soluble intercellular adhesion molecule-1. Antimicrobial Agents and Chemotherapy36:1186–1191.
8.
ArrudaECrumpCE & HaydenFG (1994) In vitro selection of human rhinovirus relatively resistant to soluble intercellular adhesion molecule-1. Antimicrobial Agents and Chemotherapy38:66–70.
9.
Bibler-MuckelbauerJKKremerMJRossmannMGDianaGDDutkoFJPevearDC & McKinlayMA (1994) Human rhinovirus 14 complexed with fragments of antiviral compounds. Virology202:360–369.
10.
BuontempoPWright-MinogueJCoxSDeMartinoJGirijavallablanVRozhonESchwartzJ & O'ConnellJ (1995) Mechanism of action of SCH 47802: an antipicornavirus molecule. Antiviral Research26 (Supplement 3): A346.
11.
ChandraRK (1984) Excessive intake of zinc impairs immune responses. Journal of the American Medical Association252:1143–1145.
12.
ChapmanMSMinorIRossmannMGDianaGD & AndriesK (1991) Human rhinovirus 14 complexed with antiviral compound R 61837. Journal of Molecular Biology217:455–463.
13.
CoxSBuontempoJWright-MinogueJSkeltonADeMartinoJRoshonELinnCGirijavallablanVSchwartzJ & O'ConnellJ (1995) Antipicornavirus activity of SCH 47802: in vitro and in vivo studies. Antiviral Research26 (Supplement 3): A345.
14.
CoxSBuontempoPJWright-MinogueJDeMartinoJLSkeltonAMFerrariESchwartzJRozhonEJLinnCGirijavallablanV & O'ConnellJ (1996) Antipicornavirus activity of SCH 47802 and analogues: in vitro and in vivo studies. Antiviral Research32:71–79.
15.
CrumpCEArrudaE & HaydenFG (1993) In vitro inhibitor)' activity of soluble ICAM-1 for the numbered serotypes of human rhinovirus. Antiviral Chemistry and Chemotherapy4:323–327.
16.
DeardenCAl-NakibWAndriesKWoestenborghsR & TyrellDAJ (1989) Drug resistant rhinoviruses from the nose of experimentally treated volunteers. Archives of Virology109:71–81.
17.
DianaGDVolkotsDLNitzTJBaileyTRLongMAVescioNAldousSPevearDC & DutkoFJ (1994) Oxadiazoles as ester bioisosteric replacements in compounds related to disoxaril. Antirhinovirus activity. Journal of Medicinal Chemistry37:2421–2436.
18.
DianaGDRudewiczPPevearDCNitzTJAldousSCAldousDJRobinsonDTDraperTDutkoFJAldiCGendronGOglesbyRCVolkotsDLReumanMBaileyTRCzerniakRBlockTRolandR & OppermannJ (1995) Picornavirus inhibitors: trifluoromethyl substitution provides a global protective effect against hepatic metabolism. Journal of Medicinal Chemistry38:1355–1371.
19.
DouglasEMMilesHBMooreBWRyanP & PinnockCB (1987) Failure of effervescent zinc acetate lozenges to alter the course of upper respiratory tract infections in Australian adults. Antimicrobial Agents and Chemotherapy31:1263–1265.
20.
DustinML & SpringerTA (1988) Lymphocyte function associated antigen-1 (LFA- 1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. Journal of Cell Biology107:321–331.
21.
EbyGADavisDR & HalcombWW (1984) Reduction in duration in common colds by zinc gluconate lozenges in a double-blind study. Antimicrobial Agents and Chemotherapy25:20–24.
22.
FarrBM & GwaltneyJMJr (1987) The problems of taste in placebo matching an evaluation of zinc gluconate for the common cold. Journal of Chronic Diseases40:875–879.
23.
FarrBMConnerEMBettsRFOleskeJMinniferA & GwaltneyJMJr (1987) Two randomized controlled trials of zinc gluconate lozenge therapy of experimentally induced rhinovirus colds. Antimicrobial Agents and Chemotherapy8:1183–1187.
24.
GeistFCBatemanJA & HaydenFG (1987) In vitro activity of zinc salts against human rhinovirus. Antimicrobial Agents and Chemotherapy31:622–624.
25.
GirandaVLChapmanMS & RossmannMG (1990) Modeling of the human intercellular adhesion molecule-1, the human rhinovirus major group receptor. Proteins7:227–233.
26.
GreveJMDavisGMeyerAMForteCPYostSCMarlorCWKamarckME & McClellandA (1989) The major rhinovirus receptor is ICAM-1. Cell56:849–853.
27.
GreveJMFortesCPMarlorCWMeyerAMHoover-LittyHWunderlichD & McClellandA (1991) Mechanism of receptor-mediated rhinovirus neutralization defined by two soluble forms of ICAM-1. Journal of Virology65:6015–6023.
28.
HaydenFG & GwaltneyJMJr (1982) Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection. Antimicrobial Agents and Chemotherapy21:892–897.
29.
HaydenFGAndriesK & JanssenPA (1992) Safety and efficacy of intranasal pirodavir (R 77975) in experimental rhinovirus infection. Antimicrobial Agents and Chemotherapy36:727–732.
30.
HaydenFGEisenGJanssenMAndriesK & JanssenP (1993) Safety and efficacy of intranasal pirodavir (R 77975) for treatment of naturally occurring common colds. Antimicrobial Agents and Chemotherapy36:727–732.
31.
HeinzBA & VanceLM (1995) The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. Journal of Virology69:4189–4197.
32.
HigginsPGBarrowGI & TyrellDAJ (1990) A study of the efficacy of the bradykinin antagonist, NPC 567, in rhinovirus infections in human volunteers. Antiviral Research14:339–344.
33.
HoferFGruenbergerMKowalskiHMachatHHuettingerMKuechlerE & BlaasD (1994) Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. Proceedings of the National Academy of Sciences, USA91:1839–1842.
34.
IshitsukaHNinomiyaYTOhsawaCFujiuM & SuharaY (1982a) Direct and specific inactivation of rhinovirus by chalcone Ro 09–0410. Antimicrobial Agents and Chemotherapy22:617–621.
KaplanGPetersD & RacanielloVR (1990) Poliovirus mutants resistant to neutralization with soluble cell receptors. Science250:1596–1599.
37.
KimSSmithTJChapmanMSRossmannMGPevearDCDutkoFJFelockPTDianaGD & McKinlayMA (1989) Crystal structure of human rhinovirus serotype 1A (HRV 1A). Journal of Molecular Biology210:91–111.
38.
KimSWillingmannPGongZXKremerMJChapmanMSMinorIOlivieraMARossmannMGAndriesKDianaGDDutkoFJMcKinkyMA & PevearDC (1993) A comparison of the antirhinoviral drug binding pocket in HRV 14 and HRV 1A. Journal of Molecular Biology230:206–227.
39.
KorantBD & ButterworthBE (1976) Inhibition by zinc of rhinovirus protein cleavage: interaction of zinc with capsid polypeptides. Journal of Virology18:298–306.
40.
Lonberg-HolmK & KorantBD (1972) Early interaction of rhinoviruses with host cells. Journal of Virology9:29–49.
41.
MadshusIHOlsnesS & SandvigK (1984) Different pH requirements for entry of the two picornaviruses, human rhinovirus 2 and murine encephalomyocarditis virus. Virology139:346–357.
42.
MallamoJPDianaGDPevearDCDutkoFJChapmanMSKimKHMinorIOlivieraM & RossmannMG (1992) Conformationally restricted analogues of disoxaril: a comparison of the activities against human rhinovirus types 14 and 1A. Journal of Medicinal Chemistry35:4690–4695.
43.
MartinSDStauntonDESpringerTAStratowaCSommergruberW & MerluzziVJ (1990) A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection. Nature344:70–72.
44.
MartinSCasanovasJMStauntonDE & SpringerTA (1993) Successful prevention of rhinovirus infections with chimeric ICAM-1 immunoglobulin in vitro. Medizinishe Klinik88:193–197.
45.
MillerFDMontoASDeLongDCExelbyABryanER & SrivastavaS (1985) Controlled trial of enviroxime against natural rhinovirus infections in a community. Antimicrobial Agents and Chemotherapy27:102–106.
46.
MontoASSchwartzSA & AlbrechtJK (1989) Ineffectiveness of post exposure prophylaxis of rhinovirus infection with low-dose intranasal alpha interferon in families. Antimicrobial Agents and Chemotherapy33:387–390.
47.
MuckelbauerJKKremerMMinorIDianaGDutkoFJGroarkeJPevearDC & RossmannMG (1995) The structure of coxsackievirus B3 at 3.5Å resolution. Structure3:653–667.
48.
NeubauerCFraselLKuechlerE & BlaasD (1987) Mechanism of entry of human rhinovirus 2 into HeLa cells. Virology158:255–258.
49.
NinomiyaYOhasawaCAoyamaMUmedaISuharaY & IshitsukaH (1984) Antivirus agent Ro 09–0410 binds to rhinovirus specifically and stabilizes the virus conformation. Virology134:269–276.
50.
NinomiyaYAoyamaMUmedaISuharaY & IshitsukaH (1985) Comparative studies on the modes of action of the antirhinovirus agent Ro 09–0410, Ro 09–0179, RMI-15,731,4′6-dichloroflavin and enviroxime. Antimicrobial Agents and Chemotherapy27:595–599.
51.
NinomiyaYShimmaN & IshitsukaH (1990) Comparative studies on the antirhinovirus activity and mode of action of the rhinovirus capsid binding agents, chalcone amides. Antiviral Research13:61–64.
52.
NovickSGGodfroyJCGodfreyNJ & WilderHR (1996) How does zinc modify the common cold? Clinical observation and implications regarding mechanisms of action. Medical Hypothesis46:295–302.
53.
OhlinAHoover-LittyHSandersonGPaessensAJohnstonSLHolgateSTHuguenelE & GreveJM (1994) Spectrum of activity of intercellular adhesion molecule-1 against rhinovirus reference strains and field isolates. Antimicrobial Agents and Chemotherapy38:1413–1415.
54.
OlivieraMAZhaoRLeeWMKremerMJMinorIRueckertRRDianaGDPevearDCDutkoFJMcKinlayMA & RossmannMG (1993) The structure of human rhinovirus 16. Structure1:51–68.
55.
OlsonNHKolatkarPR & OlivieraMA (1993) Structure of the human rhinovirus complexed with its receptor molecule. Proceedings of the National Academy of Sciences, USA90:507–511.
56.
PhillpottsRJWallaceJTyrellDAJ & TagartVB (1983) Therapeutic activity of enviroxime against rhinovirus infection in volunteers. Antimicrobial Agents and Chemotherapy23:671–675.
57.
PhillpottsRJHigginsPGWillmanJSTyrellDJA & Lenox-SmithI (1984) Evaluation of antirhinovirus chalcone Ro 09-0415 given orally to volunteers. Antimicrobial Agents and Chemotherapy14:403–409.
58.
RosenwirthBKisZL & EggersHJ (1995) In vivo efficacy of SDZ 35-682, a new picornavirus capsid-binding agent. Antiviral Research26:55–64.
59.
RossmannMG & PalmenbergAC (1988) Conservation of the putative receptor attachment site in picornaviruses. Virology164:373–382.
60.
RossmannMGArnoldEEricksonJWFrankinbergerEAGriffithJPHechtHJJohnsonJEKamerGLuoMMosserAGRueckertRRSherryB & VriendG (1985) Structure of a human common cold virus and functional relationship to other picornaviruses. Nature317:145–153.
61.
RozhonECoxSBuontempoPO'ConnellJSlaterWDeMartinoJSchwartzJMillerGArnoldEZhangAMorrowCJablonskiSPintoPVersaceRDuelferT & GirijavallabhanV (1993) SCH 38057: a picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating. Antiviral Research21:15–35.
62.
RueckertRR (1987) Picornaviridae: the viruses and their replication. In Fields Virology, 2nd edn. Edited by FieldsBN & KnipeDM. New York: Lippincott Raven, pp. 507–508.
63.
SchiffGMSherwoodJRYoungECMasonLJ & GambleJN (1992) Prophylactic efficacy of WIN 54954 in prevention of experimental human coxsackie A21 infection and illness. Antiviral Research17 (Supplement 1): 92.
64.
ShepardDAHeinzBA & RueckertRR (1993) Win 52035-2 inhibits both attachment and eclipse of human rhinovirus 14. Journal of Virology67:2245–2254.
65.
SmithTJKremerMJLuoMVriendGArnoldEKamerGRossmannMGMcKinlayMADianaGD & OttoMJ (1986) The site of attachment in human rhinovirus 14 of antiviral agents that inhibit uncoating. Science233:1286–1293.
66.
SperberSJ & HaydenFG (1988) Chemotherapy of rhinovirus colds. Antimicrobial Agents and Chemotherapy32:409–419.
67.
StauntonDEMerluzziVJRothleinRBartonRMartinSD & SpringerTA (1989) A cell adhesion molecule, ICAM-1 is the major surface receptor for rhinoviruses. Cell56:849–853.
68.
TomassiniJEGrahamCMDeWittCMLinenbergerDWRodkeyJA & ColonnoRJ (1989) cDNA cloning reveals that the major group rhinovirus receptor on HeLa cells is intercellular adhesion molecule 1. Proceedings of the National Academy of Sciences, USA86:4907–4911.
69.
TurnerRB & HaydenFG (1992) Efficacy of oral WIN 54954 for the prophylaxis of experimental rhinovirus infections. Antiviral Research17 (Supplement 1): 92.
70.
TurnerRBDureanJFAlbrechtJK & CrandallAS (1989) Safety and tolerance of ocular admission of recombinant alpha interferon. Antimicrobial Agents and Chemotherapy33:396–397.
71.
WikelJHPagetCJDeLongDCNelsonJDWuCYEPaschalJWDinnerATempletonRJChaneyMOJonesND & ChamberlinJW (1980) Synthesis of syn and anti isomers of 6-[(hydroxyimmo)phenyl]-1-[(1-methyl)sulfonyl]-1H-benzimida-zole-2-amine. Inhibitors of rhinovirus multiplication. Journal of Medicinal Chemistry23:368–372.
72.
ZhangANanniRGOrenDAARozhonEJ & ArnoldE (1992) Three dimensional structure-relationship for antiviral agents that interact with picornavirus capsid. Seminars in Virology3:453–471.
73.
ZhaoRPevearDCKremerMGirandaVLKofronJAKuhnRJ & RossmannMG (1996) Human rhinovirus 3 at 3.0 A resolution. Structure4:1205–220.
